Novartis faces whistleblower claims of bribery in Turkey

Novartis ($NVS) faces bribery allegations in yet another country. A whistleblower has accused the Swiss drugmaker of paying bribes in Turkey to increase prescriptions of its drugs, Reuters reports. More from FiercePharma

Suggested Articles

A month after the FDA approved it, Esperion's Nexletol showed it can lower cholesterol regardless of statin and ezitimibe treatment.

Bluebird said it doesn't expect to complete a U.S. application for the gene therapy until mid-2021 amid COVID-19 and a lack of agreement with the FDA.

W2O Group and California Life Sciences' new data-driven platform tracks top COVID-19 news and conversations in the life science industry.